Sanofi Pasteur MSD are replacing their M-M-R II vaccine with the M-M-RvaxPro.

The formulation and new vial and pre-filled syringe presentation of M-M-RvaxPro is different from M-M-R II, but the new vaccine contains the same three virus strains and has similar immunogenicity and safety to M-M-R II.

Further information: Sanofi Pasteur MSD

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more